Dermira, Inc. is a specialty biopharmaceutical company. The Company is focused on bringing and differentiated medical dermatology products to dermatologists and their patients. The Company�s portfolio of five product candidates targets market opportunities and includes three late-stage product candidates, Cimzia (certolizumab pegol), which the Company is developing in collaboration with UCB Pharma S.A., for the treatment of moderate-to-severe plaque psoriasis, DRM04, which the Company is developing for the treatment of hyperhidrosis, or excessive sweating, and DRM01, which the Company is developing for the treatment of acne. Its three late-stage product candidates are Cimzia, DRM04 and DRM01.